BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,036 | -47.6% | 691 | -36.3% | 0.00% | – |
| Q4 2022 | $89,842 | -9.3% | 1,084 | +209.7% | 0.00% | – |
| Q3 2022 | $99,000 | -18.2% | 350 | 0.0% | 0.00% | – |
| Q2 2022 | $121,000 | -38.9% | 350 | -8.4% | 0.00% | – |
| Q4 2021 | $198,000 | +40.4% | 382 | +30.8% | 0.00% | – |
| Q3 2021 | $141,000 | -95.7% | 292 | -96.0% | 0.00% | -100.0% |
| Q2 2021 | $3,268,000 | -51.5% | 7,257 | -58.8% | 0.01% | -53.8% |
| Q1 2021 | $6,733,000 | +170.1% | 17,630 | +124.6% | 0.01% | +160.0% |
| Q4 2020 | $2,493,000 | +20.4% | 7,851 | -6.0% | 0.01% | 0.0% |
| Q3 2020 | $2,070,000 | -14.8% | 8,356 | -9.2% | 0.01% | -16.7% |
| Q2 2020 | $2,431,000 | +26.4% | 9,205 | -9.3% | 0.01% | 0.0% |
| Q1 2020 | $1,924,000 | -18.1% | 10,145 | -5.2% | 0.01% | +20.0% |
| Q4 2019 | $2,350,000 | +3.2% | 10,706 | -8.0% | 0.01% | -16.7% |
| Q3 2019 | $2,277,000 | -19.5% | 11,635 | -14.3% | 0.01% | -14.3% |
| Q2 2019 | $2,830,000 | +13.9% | 13,574 | +8.4% | 0.01% | +16.7% |
| Q1 2019 | $2,485,000 | +31.1% | 12,517 | -4.4% | 0.01% | +20.0% |
| Q4 2018 | $1,895,000 | -42.7% | 13,097 | -19.2% | 0.01% | -37.5% |
| Q3 2018 | $3,309,000 | +31.2% | 16,211 | -4.9% | 0.01% | +14.3% |
| Q2 2018 | $2,522,000 | +8.0% | 17,048 | +10.3% | 0.01% | 0.0% |
| Q1 2018 | $2,335,000 | +20.5% | 15,460 | +3.4% | 0.01% | +40.0% |
| Q4 2017 | $1,937,000 | -7.0% | 14,950 | -13.2% | 0.01% | -16.7% |
| Q3 2017 | $2,083,000 | +21.7% | 17,227 | +18.3% | 0.01% | +20.0% |
| Q2 2017 | $1,711,000 | -15.3% | 14,560 | -26.7% | 0.01% | -16.7% |
| Q1 2017 | $2,020,000 | -4.2% | 19,877 | -3.1% | 0.01% | 0.0% |
| Q4 2016 | $2,109,000 | -8.9% | 20,506 | -3.0% | 0.01% | -14.3% |
| Q3 2016 | $2,314,000 | -5.4% | 21,131 | -2.6% | 0.01% | 0.0% |
| Q2 2016 | $2,447,000 | +22.5% | 21,700 | +2.7% | 0.01% | +16.7% |
| Q1 2016 | $1,997,000 | +2.0% | 21,125 | -2.9% | 0.01% | 0.0% |
| Q4 2015 | $1,958,000 | -72.8% | 21,761 | -72.1% | 0.01% | -73.9% |
| Q3 2015 | $7,211,000 | -5.7% | 77,989 | +0.4% | 0.02% | 0.0% |
| Q2 2015 | $7,645,000 | -5.2% | 77,641 | -3.4% | 0.02% | -8.0% |
| Q1 2015 | $8,064,000 | +35.8% | 80,404 | +25.1% | 0.02% | +38.9% |
| Q4 2014 | $5,937,000 | – | 64,258 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |